References
†These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
*For best results, consume within 30mins after mixing. Do not mix with carbonated drinks
- Swidsinski, A., Loening-Baucke,V., Verstraelen, H., Osowska, S., & Doerffel, Y. (2008). Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology, 135(2), 568-579.
- Martins, F.S., Silva, A.A., Vieira, A.T., Barbosa, F.H., Arantes, R.M., et al. (2009). Comparative study of Bifidobacterium animalis, Escherichia coli, Lactobacillus casei and Saccharomyces boulardii probiotic properties. Archives of Microbiology, 191, 623-630.
- Klein, S.M., Elmer, G.W., McFarland, L.V., Surawicz, C.M., & Levy, R.H. (1993). Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharmaceutical Research, 10, 1615-1619.
- Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. (2002). Guidelines for the Evaluation of Probiotics in Food. London Ontario, Canada: FAO/WHO.
- Buts, J.P., Bernasconi, P., Van Craynest, M.P., Maldague, P., & De Meyer, R. (1986). Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatric Research, 20, 192-196.
- Schneider, S.M., Girard-Pipau, F., Filippi,J., Hebuterne, X., Moyse, D., et al. (2005). Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition. World Journal of Gastroenterology, 11, 6165-6169.
- Vandenplas, Y., Brunser, O., & Szajewska, H. (2009). Saccharomyces boulardii in childhood. European Journal of Pediatrics, 168(3), 253-265.
- Blehaut, H., Massot, J., Elmer, G.W., & Levy, R.H. (1989). Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharmaceutics & Drug Disposition, 10(4), 353-364.
- IMS Data, 2017.
- Prasad, A.S. (1994). Zinc: an overview. Nutrition, 11(1 Suppl), 93-99.
- Jacob, R.A., & Sotoudeh, G. (2002). Vitamin C function and status in chronic disease. Nutrition in clinical care, 5(2), 66-74.
- Norman, A.W., & Henry, H.H. (2006). Vitamin D. In Bowman, B.A., & Russell, R.M. (Eds.), Present Knowledge in Nutrition (9th ed.). Washington DC: ILSI Press.
- Kolida, S., & Gibson, G.R. (2007). Prebiotic capacity of inulin-type fructans. [The Journal of Nutrition, 137] (11), 2503S-2506S.
- American Museum of Natural History. Meet Your Microbiome. http://www.amnh.org/. Accessed May 15, 2017.
- Kabbani, T. A., Pallav, K., Dowd, S. E., Villafuerte-Galvez, J., Vanga, R. R., et al. (2017). Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers. Gut Microbes, 1, 17-32.
- Moores, J. (2013). Vitamin C: a wound healing perspective. British journal of community nursing, 18.
- Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academy Press, 2010.
- Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academy Press, 2001.
- Institute of Medicine. Food and Nutrition Board. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington, DC: National Academy Press, 2000.
- Veereman G. (2007) Pediatric applications of inulin and oligofructose. The Journal of nutrition, 137(11), 2585S-2589S.
- Abrams SA, Hawthorne KM, Aliu O, Hicks PD, Chen Z, & Griffin IJ. (2007) An inulin-type fructan enhances calcium absorption primarily via an effect on colonic absorption in humans. The Journal of nutrition, 137(10), 2208-2212.
- Coussement PA. (1999). Inulin and oligofructose: safe intakes and legal status. The Journal of nutrition, 129(7), 1412S-1417s.